Loading company
Cyclo Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $1.1 million | $1.4 million | -21.8% | 10-K 2024-03-18 · proof |
| Gross profit | $992,038 | $1.2 million | -19.8% | 10-K 2024-03-18 · proof |
| Operating income | -$20.1 million | -$15.6 million | 10-K 2024-03-18 · proof | |
| Net income | -$20.1 million | -$15.5 million | 10-K 2024-03-18 · proof | |
| Cash from operating activities | -$16.2 million | -$15.1 million | 10-K 2024-03-18 · proof | |
| Free cash flow | -$16.2 million | -$15.1 million | 10-K 2024-03-18 · proof | |
| Total assets | $13.2 million | $4.2 million | +214.3% | 10-K 2024-03-18 · proof |
| Total liabilities | $8.5 million | $3.5 million | +143.9% | 10-K 2024-03-18 · proof |
| Cash and cash equivalents | $9.2 million | $1.5 million | +499.1% | 10-K 2024-03-18 · proof |
- What was Cyclo Therapeutics, Inc.'s revenue in fiscal 2023?
- Cyclo Therapeutics, Inc. reported revenue of $1.1 million for fiscal 2023 (the year ended Dec 31, 2023), against $1.4 million the year before (-21.8%). Source: the 10-K filed with the SEC on Mar 18, 2024. SEC
- What was Cyclo Therapeutics, Inc.'s gross profit in fiscal 2023?
- Cyclo Therapeutics, Inc. reported gross profit of $992,038 for fiscal 2023 (the year ended Dec 31, 2023), against $1.2 million the year before (-19.8%). Source: the 10-K filed with the SEC on Mar 18, 2024. SEC
- What was Cyclo Therapeutics, Inc.'s operating income in fiscal 2023?
- Cyclo Therapeutics, Inc. reported operating income of -$20.1 million for fiscal 2023 (the year ended Dec 31, 2023), against -$15.6 million the year before. Source: the 10-K filed with the SEC on Mar 18, 2024. SEC
- What was Cyclo Therapeutics, Inc.'s net income in fiscal 2023?
- Cyclo Therapeutics, Inc. reported net income of -$20.1 million for fiscal 2023 (the year ended Dec 31, 2023), against -$15.5 million the year before. Source: the 10-K filed with the SEC on Mar 18, 2024. SEC
- What was Cyclo Therapeutics, Inc.'s cash from operating activities in fiscal 2023?
- Cyclo Therapeutics, Inc. reported cash from operating activities of -$16.2 million for fiscal 2023 (the year ended Dec 31, 2023), against -$15.1 million the year before. Source: the 10-K filed with the SEC on Mar 18, 2024. SEC
- What was Cyclo Therapeutics, Inc.'s free cash flow in fiscal 2023?
- Cyclo Therapeutics, Inc. reported free cash flow of -$16.2 million for fiscal 2023 (the year ended Dec 31, 2023), against -$15.1 million the year before. Source: the 10-K filed with the SEC on Mar 18, 2024. SEC
- What are Cyclo Therapeutics, Inc.'s total assets?
- As of Dec 31, 2023, Cyclo Therapeutics, Inc. reported total assets of $13.2 million, against $4.2 million a year earlier (+214.3%). Source: the 10-K filed with the SEC on Mar 18, 2024. SEC
- What are Cyclo Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2023, Cyclo Therapeutics, Inc. reported total liabilities of $8.5 million, against $3.5 million a year earlier (+143.9%). Source: the 10-K filed with the SEC on Mar 18, 2024. SEC
- What are Cyclo Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2023, Cyclo Therapeutics, Inc. reported cash and cash equivalents of $9.2 million, against $1.5 million a year earlier (+499.1%). Source: the 10-K filed with the SEC on Mar 18, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:922247&period_type=annual&limit=5"Information only, not investment advice.